New management strategy of pregnancies at risk of congenital adrenal hyperplasia using fetal sex determination in maternal serum: French cohort of 258 cases (2002-2011)

Journal of Clinical Endocrinology and Metabolism

Volumn 99, Issue 4, 2014, Pages 1180-1188

  Tardy Guidollet, Véronique ^a   Menassa, Rita ^a   Costa, Jean Marc ^b   David, Michel ^c   Bouvattier Morel, Claire ^d,e   Baumann, Clarisse ^f   Houang, Muriel ^g   Lorenzini, Françoise ^h   Philip, Nicole ⁱ   Odent, Sylvie ^j   Guichet, Agnès ^k   Morel, Yves ^a  

^a HOSPICES CIVILS DE LYON   (France)

^b LABORATOIRE CERBA   (France)

^c Hôpital Mère Enfants Groupe Hospitalier Est   (France)

^d BICÊTRE HOSPITAL   (France)

^e ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^f HÔPITAL ROBERT DEBRÉ   (France)

^g ARMAND TROUSSEAU HOSPITAL   (France)

^h Paul Sabatier University   (France)

ⁱ TIMONE HOSPITAL   (France)

^j SERVICE DE RHUMATOLOGIE   (France)

^k ANGERS UNIVERSITY HOSPITAL   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ADRENAL HYPERPLASIA, CONGENITAL; BLOOD CHEMICAL ANALYSIS; COHORT STUDIES; DEXAMETHASONE; FEMALE; FETAL THERAPIES; FRANCE; HUMANS; MALE; MATERNAL-FETAL EXCHANGE; PREGNANCY; PRENATAL DIAGNOSIS; RISK FACTORS; SEX DETERMINATION ANALYSIS; VIRILISM;

EID: 84898471193     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2013-2895     Document Type: Article

References (40)

1. New MI, Gertner JM, Speiser PW, Del Balzo P. Growth and final height in classical and nonclassical 21-hydroxylase deficiency. J En-docrinolInvest. 1989;12:91-95.
2. Morel Y, Miller WL. Clinical and molecular genetics of congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Adv Hum Genet. 1991;20:1-68.
3. David M, Forest MG. Prenatal treatment of congenital adrenal hyperplasia resulting from 21-hydroxylase deficiency. J Pediatr. 1984; 105:799-803.
4. Forest MG, Betuel H, David M. Prenatal treatment in congenital adrenal hyperplasia due to 21-hydroxylase deficiency: up-date 88 of the French multicentric study. Endocr Res. 1989;15:277-301.
5. Dorr HG, Sippell WG. Prenatal dexamethasone treatment in pregnancies at risk for congenital adrenal hyperplasia due to 21-hydrox-ylase deficiency: effect on midgestational amniotic fluid steroid levels. J Clin Endocrinol Metab. 1993;76:117-120.
6. Forest MG, David M, Morel Y. Prenatal diagnosis and treatment of 21-hydroxylase deficiency. J Steroid Biochem Mol Biol. 1993;45: 75-82.
7. Mercado AB, Wilson RC, Cheng KC, Wei JQ, New MI. Prenatal treatment and diagnosis of congenital adrenal hyperplasia owing to steroid 21-hydroxylase deficiency. J Clin Endocrinol Metab. 1995; 80:2014-2020.
8. Lajic S, Wedell A, Bui TH, Ritzen EM, Holst M. Long-term somatic follow-up of prenatally treated children with congenital adrenal hy-perplasia. J Clin Endocrinol Metab. 1998;83:3872-3880.
9. Forest MG, Dorr HG. Prenatal therapy in congenital adrenal hy-perplasia due to 21-hydroxylase deficiency: retrospective follow-up study of 253 treated pregnancies in 215 families. Endocrinologist. 2003;13:252-258.
10. Joint LWPES/ESPE CAH Working Group. Consensus statement on 21-hydroxylase deficiency from the Lawson Wilkins Pediatric Endocrine Society and the European Society for Paediatric Endocrinology 2002. J Clin Endocrinol Metab. 2002;87:4048-4053.
11. Gorduza D, Vidal I, Birraux J, et al. The surgical challenges of disorders of sex development (DSD). Arch Esp Urol. 2010;63:495-504.
12. Pang S, Clark A. Newborn screening, prenatal diagnosis, and prenatal treatment of congenital adrenal hyperplasia due to 21-hydrox-ylase deficiency. Trends Endocrinol Metab. 1990;1:300-307.
13. New MI, Carlson A, ObeidJ, et al. Prenatal diagnosis for congenital adrenal hyperplasia in 532 pregnancies. J Clin Endocrinol Metab. 2001;86:5651-5657.
14. Uno H, Lohmiller L, Thieme C, et al. Brain damage induced by prenatal exposure to dexamethasone in fetal rhesus macaques. I. Hippocampus. Brain Res Dev Brain Res. 1990;53:157-167.
15. Nimkarn S, NewMI. Prenatal diagnosis and treatment ofcongenital adrenal hyperplasia due to 21-hydroxylase deficiency. Mol Cell En-docrinol. 2009;300:192-196.
16. Forest MG, Morel Y, David M. Prenatal treatment of congenital adrenal hyperplasia. Trends Endocrinol Metab. 1998;9:284-289.
17. Lajic S, Nordenstrom A, Ritzen EM, Wedell A. Prenatal treatment of congenital adrenal hyperplasia. Eur J Endocrinol. 2004; 151(Suppl3):U63-U69.
18. Hirvikoski T, Nordenstrom A, Lindholm T, et al. Cognitive functions in children at risk for congenital adrenal hyperplasia treated prenatally with dexamethasone. J Clin Endocrinol Metab. 2007; 92:542-548.
19. Meyer-Bahlburg HF, Dolezal C, Baker SW, Carlson AD, Obeid JS, New MI. Cognitive and motor development of children with and without congenital adrenal hyperplasia after early-prenatal dexa-methasone. J Clin Endocrinol Metab . 2004;89:610-614.
20. Meyer-Bahlburg HF, Dolezal C, Haggerty R, Silverman M, New MI. Cognitive outcome of offspring from dexamethasone-treated pregnancies at risk for congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Eur J Endocrinol. 2012;167:103-110.
21. Speiser PW, Azziz R, Baskin LS, et al. Congenital adrenal hyper-plasia due to steroid 21-hydroxylase deficiency: an Endocrine Society clinical practice guideline. JClin Endocrinol Metab. 2010;95: 4133-4160.
22. Merce Fernandez-Balsells M, Muthusamy K, Smushkin G, et al. Prenatal dexamethasone use for the prevention of virilization in pregnancies at risk for classical congenital adrenal hyperplasia because of 21-hydroxylase (CYP21A2) deficiency: a systematic review and meta-analyses. Clin Endocrinol (Oxf). 2010;73:436-444.
23. Miller WL, Witchel SF. Prenatal treatment of congenital adrenal hyperplasia: risks outweigh benefits. Am J Obstet Gynecol. 2013; 208:354-359.
24. Hirvikoski T, Nordenstrom A, Wedell A, Ritzen M, Lajic S. Prenatal dexamethasone treatment of children at risk for congenital adrenal hyperplasia: the Swedish experience and standpoint. J Clin Endo-crinol Metab. 2012;97:1881-1883.
25. Lo YM, Corbetta N, Chamberlain PF, et al. Presence of fetal DNA in maternal plasma and serum. Lancet. 1997;350:485-487.
26. CostaJM, Benachi A, GautierE,JouannicJM, Ernault P, Dumez Y. First-trimester fetal sex determination in maternal serum using realtime PCR. Prenat Diagn. 2001;21:1070-1074.
27. Bartha JL, Finning K, Soothill PW. Fetal sex determination from maternal blood at 6 weeks of gestation when at risk for 21-hydrox-ylase deficiency. Obstet Gynecol. 2003;101:1135-1136.
28. Rijnders RJ, Van Der Luijt RB, Peters ED, et al. Earliest gestational age for fetal sexing in cell-free maternal plasma. Prenat Diagn. 2003; 23:1042-1044.
29. Illanes S, Denbow M, Kailasam C, Finning K, Soothill PW. Early detection of cell-free fetal DNA in maternal plasma. Early Hum Dev. 2007;83:563-566.
30. Tardy V. Management of pregnancies at risk of 21-hydroxylase or 11-hydroxylase deficiency using fetal sex determination in maternal serum proposed in France since 2002: how to limit prenatal exposure to dexamethasone. Horm Res. 2009;70(Suppl 3):348.
31. Menassa R, Tardy V, Despert F, et al. p.H62L, a rare mutation of the CYP21 gene identified in two forms of 21-hydroxylase deficiency. J Clin Endocrinol Metab. 2008;93:1901-1908.
32. Odeh M, Granin V, Kais M, Ophir E, Bornstein J. Sonographic fetal sex determination. Obstet Gynecol Surv. 2009;64:50-57.
33. Hill M, Finning K, Martin P, et al. Non-invasive prenatal determination of fetal sex: translating research into clinical practice. Clin Genet. 2010;80:68-75.
34. Bustamante-Aragones A, Rodriguez de Alba M, Perlado S, et al. Non-invasive prenatal diagnosis of single-gene disorders from maternal blood. Gene. 2012;504:144-149.
35. Mesiano S, Jaffe RB. Developmental and functional biology of the primate fetal adrenal cortex. Endocr Rev. 1997;18:378-403.
36. Narasaka T, Suzuki T, Moriya T, Sasano H. Temporal and spatial distribution of corticosteroidogenic enzymes immunoreactivity in developing human adrenal. Mol Cell Endocrinol. 2001;174:111-120.
37. Goto M, Piper Hanley K, Marcos J, et al. In humans, early cortisol biosynthesis provides a mechanism to safeguard female sexual development. J Clin Invest. 2006;116:953-960.
38. Gastaud F, Bouvattier C, Duranteau L, et al. Impaired sexual and reproductive outcomes in women with classical forms of congenital adrenal hyperplasia. J Clin Endocrinol Metab. 2007;92:1391-1396.
39. Crouch NS, Liao LM, Woodhouse CR, Conway GS, Creighton SM. Sexual function and genital sensitivity following feminizing genito-plasty for congenital adrenal hyperplasia. J Urol. 2008;179:634-638.
40. Nordenstrom A, Frisen L, Falhammar H, et al. Sexual function and surgical outcome in women with congenital adrenal hyperplasia due to CYP21A2 deficiency: clinical perspective and the patients' perception. J Clin Endocrinol Metab . 2010;95:3633-3640.